ROCKVILLE, Md., March 9, 2016 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused
on developing therapeutics to protect the gut microbiome, announced
today that Jeffrey Riley, President
& Chief Executive Officer, is scheduled to present at the
28th Annual ROTH Conference being held March 14-16 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to
present on Wednesday, March 16, 2016
at 8:30 a.m. (Pacific
Time)/11:30 a.m. (Eastern
Time).
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the web at
http://wsw.com/webcast/roth30/syn/index.aspx. After the
presentation, a replay will be archived and accessible for 60 days
at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development are: (1) SYN-010 which is intended to reduce
the impact of methane producing organisms in the gut microbiome to
treat an underlying cause of irritable bowel syndrome with
constipation (IBS-C) and (2) SYN-004 which is designed to protect
the gut microbiome from the effects of certain commonly used
intravenous (IV) antibiotics for the prevention of C. difficile
infection and antibiotic-associated diarrhea (AAD). In
collaboration with Intrexon Corporation (NYSE: XON), the Company is
also developing preclinical stage monoclonal antibody therapies for
the prevention and treatment of Pertussis and discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-28th-annual-roth-conference-300233087.html
SOURCE Synthetic Biologics, Inc.